Lucid Diagnostics (NASDAQ:LUCD) Releases Earnings Results

Lucid Diagnostics (NASDAQ:LUCD) issued its earnings results on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, Yahoo Finance reports. Lucid Diagnostics had a negative return on equity of 8,334.14% and a negative net margin of 2,169.07%. The firm had revenue of $1.04 million for the quarter. During the same period in the prior year, the firm earned ($0.22) EPS.

Lucid Diagnostics Stock Performance

NASDAQ LUCD opened at $0.99 on Thursday. Lucid Diagnostics has a fifty-two week low of $0.97 and a fifty-two week high of $1.85. The business has a 50 day moving average price of $1.29 and a two-hundred day moving average price of $1.34.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $2.50 target price on shares of Lucid Diagnostics in a report on Wednesday. Cantor Fitzgerald decreased their target price on Lucid Diagnostics from $3.80 to $3.00 and set an “overweight” rating for the company in a report on Wednesday.

Hedge Funds Weigh In On Lucid Diagnostics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Lucid Diagnostics in the 4th quarter worth approximately $29,000. LPL Financial LLC boosted its holdings in Lucid Diagnostics by 97.2% in the 3rd quarter. LPL Financial LLC now owns 28,400 shares of the company’s stock worth $33,000 after acquiring an additional 14,000 shares during the period. Citadel Advisors LLC purchased a new position in Lucid Diagnostics in the 2nd quarter worth approximately $87,000. BlackRock Inc. boosted its holdings in Lucid Diagnostics by 39.5% in the 2nd quarter. BlackRock Inc. now owns 26,304 shares of the company’s stock worth $37,000 after acquiring an additional 7,448 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Lucid Diagnostics by 245.3% in the 2nd quarter. Geode Capital Management LLC now owns 143,465 shares of the company’s stock worth $199,000 after acquiring an additional 101,922 shares during the period. Hedge funds and other institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.